Â鶹ӳ»­

8¨C9:30 a.m. | Room 160

Optimizing precision with MARS LDR brachytherapy for prostate cancer treatment in the monotherapy, combined and salvage settings
8:24¨C8:36 a.m.
Presenter:

8 a.m.¨C5:30 p.m. | Room 204

Opening keynote: The physics advances in modern radiotherapy
8:05¨C9:05 a.m.
Presenter:

Session 1 ¡ª Re-irradiation: Data driven decision-making: Imaging/dose escalation in trials
9:30¨C9:55 a.m.
Presenter:

10¨C11 a.m. | Room 160

Optimizing precision with MARS LDR brachytherapy for prostate cancer treatment in the monotherapy, combined, and salvage settings
10¨C10:12 a.m.
Presenter:

11 a.m.¨C5:15 p.m. | Room 156

Panel: AI and Residency
3:10-4 p.m.
Panelist:

Keynote: Financial toxicity
4:05¨C4:30 p.m.
Presenter:

12¨C4 p.m. | Room 153

Intern year and transitioning to RadOnc residency w/ Q&A
3¨C3:45 p.m.
Moderator:
Panelist: Cira Mollings Puentes, M.D.

1¨C2:30 p.m. | Room 254

RO review committee information and RC program requirement changes and initiatives
1¨C1:45 p.m.
Presenter:

8:20¨C9:40 a.m. | Grand Ballroom

8:55¨C9:10 a.m.
Presenter:

11 a.m.¨C3:30 p.m. | Room 153

Mentoring lighting rounds
1:40¨C2:10 p.m.
Presenter:

1:30¨C3 p.m. | Grand Ballroom

Abstract 6 ¡ª Evaluation of PAM50 molecular subtypes in post-prostatectomy salvage radiotherapy: An NRG oncology-RTOG 0534 analysis
1:30¨C1:40 p.m.
Presenter:

Abstract 9 ¡ª Six-year overall survival of nivolumab following stereotactic ablative radiotherapy in early-stage non-small cell lung cancer: Randomized I-SABR trial
2¨C2:10 p.m.
Presenter:

2:30¨C4 p.m. | Room 257
Moderator:

3¨C4 p.m. | Room 256

Abstract 1007 ¡ª Radiation oncology workflow-integrated coronary artery disease risk calculator for pediatric and adolescent cancer patients
3:10¨C3:15 p.m.
Presenter:

Abstract 1008 ¡ª Delays in adjuvant therapy initiation for Wilms tumor: Institutional patterns and clinical impact on disease control
3:15¨C3:20 p.m.
Presenter: Troy Kleber, M.D.

3¨C4 p.m. | Room 205
Moderator:

3¨C4 p.m. | Room 204

Abstract 123 ¡ª Clonal hematopoiesis following radiation therapy as a novel predictor of cancer control and survival: Analyses from prospective trials
3:20¨C3:30 p.m.
Presenter:

3¨C4 p.m. | Room 258

Nonoperative management after neoadjuvant systemic therapy: Image guided biopsy strategies, omission of surgery, and patient reported outcomes
3:02¨C3:17 p.m. 
Presenter:

3¨C4 p.m. | Room 156

3¨C3:10 p.m.
Presenter:

5¨C6 p.m. | Room 157
Moderator:

Question and answers
5:47¨C6 p.m. 
Presenter:

c

5¨C6 p.m. | Room 259????

Breast cancer with fungating breast mass
Presenter:

5¨C6 p.m. | Room 109
Moderator:

8¨C9 a.m. | Room 107

Abstract 153 ¡ª Alternative cancer treatment clinics in North America: Evidence gaps, regulatory concerns and financial burden
8:40¨C8:50 a.m.
Presenter: Zakaria El Kouzi, M.D.

8¨C9 a.m. | Room 204???

Tumor-immune dynamics in SFRT: Modeling response, competition and treatment optimization
8:17¨C8:32 a.m.
Presenter:

10:45 a.m.¨C12 p.m. | Room 253

Hypofractionated RT for localized prostate cancer
11:17¨C11:45 a.m.
Presenter:

10:45 a.m.¨C12 p.m. | Room 259
Moderator:

1:30¨C3 p.m. | Grand Ballroom

Discussion
2:44¨C2:48 p.m.
Discussant:

3¨C4 p.m. | Room 254

Abstract 1047 ¡ª Predicting survival and treatment completion of proton craniospinal irradiation in leptomeningeal disease: A prognostic nomogram
3:30¨C3:35 p.m.
Presenter: Tejaswi Kanala, M.D., M.B.B.S.

3¨C4 p.m. | Room 205

Discussion 
3:50¨C4 p.m. 
Presenter:

3¨C4 p.m. | Room 254

1044 ¡ª Proton vs. photon craniospinal irradiation for leptomeningeal disease: Comparative clinical outcomes and acute toxicities
Presenter:

12:30¨C1:45 p.m. | Room 107

Abstract 265 ¡ª FLASH radiotherapy prevents lymphopenia and downstream immunosuppression via Chk1-STAT3 axis regulation in preclinical thoracic irradiation
1:20¨C1:30 p.m.
Presenter:

12:30¨C1:30 p.m. | Room 109
Moderator: Molly Tate, Ph.D.

Question and answers
1:05¨C1:25 p.m.
Presenter: Molly Tate, Ph.D.

2:15¨C3:30 p.m. | Room 109

Health disparities and comparative effectiveness research
2:17¨C2:37 p.m. 
Presenter:

2:15¨C3:30 p.m. | Room 162
Moderator:

2:15¨C3:30 p.m. | Room 253

Abstract 308 ¡ª Patterns of nodal failure after cervical cancer chemoradiotherapy: The role of geometric miss and baseline nodal signal
2:55¨C3:05 p.m.
Presenter:

2:15¨C4:15 p.m. | Room 153
Moderator:

Introductions, NIH review criteria
2:15¨C2:30 p.m.
Presenter:

Specific aims
2:30¨C2:45 p.m.
Presenter:

3:45¨C5 p.m. | Room 210

Abstract 315 ¡ª Long-term transcriptomic analysis of NRG/RTOG 9601: A Phase 3 study of salvage radiotherapy for prostate cancer with or without anti-androgen therapy
4:25¨C4:35 p.m.
Presenter: . 

3:45¨C5 p.m. | Room 253

Discussion
4:45¨C4:55 p.m.
Presenter:

3:45¨C5 p.m. | Room 254

Abstract 330 ¡ª SOAR-HN: A Phase 2 randomized trial of stereotactic body radiotherapy vs. conventionally fractionated reirradiation for previously treated, unresectable head and neck cancer
3:55¨C4:05 p.m.
Presenter:

3:45¨C5 p.m. | Room 205

Role of biomarkers in renal cell cancer
4:32¨C4:47 p.m.
Presenter: 

3:45¨C5 p.m. | Room 156 

Abstract 348 ¡ª Characterizing stereotactic radiosurgery plan quality across the community: Imaging and Radiation Oncology Core (IROC) Phantom Audit Program 
4:45¨C4:55 p.m. 
Presenter: Lian Duan 

5:15¨C6:15 p.m. | Room 162 

Molecular glioblastoma: The latest updates in classification and management 
5:17¨C5:32 p.m. 
Presenter:?

5:15¨C6:15 p.m. | Room 109 

Provider solutions to addressing financial toxicity: Improving affordability at the bedside 
5:47¨C6:02 p.m. 
Presenter:

5:15¨C6:15 p.m. | Room 257 

Question and answers
5:50¨C6:10 p.m. 
Moderator:

5:15¨C6:15 p.m. | Room 254 
Moderator:

5:15¨C6:15 p.m. | Room 256 

Abstract 1189 ¡ª Development stage-specific breast dose reconstruction in childhood cancer survivors: A new foundation for subsequent breast cancer risk modeling 
5:30¨C5:35 p.m.  
Presenter: Taylor Meyers 

5:15¨C6:15 p.m. | Room 210 
Moderator:

Abstract 1202 ¡ª The role of adjuvant primary site radiotherapy in the treatment of melanoma with perineural invasion 
5:30¨C5:35 p.m. 
Presenter: Riya Patel 

5:15¨C6:15 p.m. | Room 156 

Reirradiation strategies 
5:47¨C6:02 p.m. 
Presenter:

8¨C9 a.m. | Room 153 

Global implementation of RPA: Lessons from clinical integration in South Africa 
8:17¨C8:32 a.m. 
Presenter:

8¨C9 a.m. | Room 259 
Moderator/discussant:

8¨C8:30 a.m. | Room 109

Abstract 6 ¡ª Evaluation of PAM50 molecular subtypes in post-prostatectomy salvage radiotherapy: An NRG oncology-RTOG 0534 analysis
8:15¨C8:20 p.m.
Presenter:

8¨C9 a.m. | Room 160

Abstract 1210 ¡ª Modernizing the MD Anderson Stiefel Oropharynx Cancer Cohort Database through development and validation of automated data extraction algorithms 
8:30¨C8:35 a.m. 
Presenter: Waree Rinsurongkawong, Ph.D. 

8¨C9 a.m. | Room 156 
Moderator:

Question and answer 
8:35¨C8:55 a.m. 
Moderator:

9:15¨C9:45 a.m. | Room 109
Moderator/discussant:

9:15¨C9:45 a.m. | Room 162

Abstract 9 ¡ª Six-year overall survival of nivolumab following stereotactic ablative radiotherapy in early-stage non-small cell lung cancer: Randomized I-SABR trial
9:35¨C9:40 a.m.
Presenter:

9:15¨C9:45 a.m. | Room 160

Abstract 355 ¡ª Prophylactic cement augmentation for patients at high risk for developing vertebral body compression fracture following spine stereotactic radiosurgery: A randomized Phase 2 clinical trial
9:15¨C9:25 a.m.
Presenter:

9:15¨C10:15 a.m. | Room 157 

Abstract 1244 ¡ª Nanoray pancreas: Biomarker insights of NBTXR3 activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC) 
9:35¨C9:40 a.m. 
Presenter: Kasey Cargill, M.D., Ph.D. 

10:45¨C11:45 a.m. | Room 157
Moderator/discussant:

3¨C4 p.m.

Abstract 2039 ¡ª Association of serum metabolomic signatures with survival in pancreatic cancer patients undergoing neoadjuvant therapy
Presenter: Diya Choudhary

Abstract 2041 ¡ª Risk factors for treatment-related effects in brainstem metastases following stereotactic radiosurgery
Presenter: Darien Colson-Fearon, M.D.

Abstract 2114 ¡ª Fifteen-year longitudinal analysis of spine stereotactic radiosurgery for metastatic thyroid cancer
Presenter: Ryan Ko, M.D.

Abstract 2134 ¡ª Comparative analysis of the impact of proton vs. photon-based chemoradiation in esophageal cancer patients on peripheral blood lymphocyte profile and clonal diversity using single cell combinational sequencing
Presenter:

4¨C5 p.m. 

Abstract 2309 ¡ª Evaluating the effect of tumor-draining nodal irradiation by flash vs. conventional dose-rate radiotherapy of a clinically relevant melanoma mouse model
Presenter: Patrick Carriere, M.D., Ph.D.

Abstract 2321 ¡ª SATURN-STS: Phase 2 study of neoadjuvant atezolizumab with doxorubicin, concurrent atezolizumab with preoperative radiotherapy and adjuvant atezolizumab in patients with high-risk surgically resectable extremity and truncal soft tissue sarcoma
Presenter:

Abstract 2323 ¡ª Proton vs. photon radiotherapy for patients with oropharyngeal cancer in the USA: A cost-effectiveness analysis
Presenter:

Abstract 2326 ¡ª Radiation pneumonitis after contemporary whole lung irradiation in pediatric sarcomas and Wilms tumor
Presenter: Ory Haisraely, M.D.

Abstract 2337 ¡ª Outcomes following combined modality local therapy vs. surgery alone for patients with non-metastatic intrathoracic soft tissue sarcomas 
Presenter: Tejaswi Kanala, M.D., M.B.B.S.

Abstract 2354 ¡ª Long-term outcomes for localized leiomyosarcoma of the extremity and superficial trunk treated with surgery and radiation therapy
Presenter: Jordan McDonald, M.D.

10:45 a.m.¨C12 p.m.

Abstract 2454 ¡ª Multidisciplinary rapid access bone metastasis clinic: Expeditious workflow from referral to palliative radiotherapy
Presenter: Ahmed Fetooh, M.D.

Abstract 2469 ¡ª Incorporation of variable RBE in radiation-induced lymphopenia prediction risk modeling for proton therapy
Presenter: Madison Grayson

Abstract 2551 ¡ª Carbon ion radiotherapy synergizes with KRASG12D inhibition to overcome acquired resistance in pancreatic cancer
Presenter: Henry Meyer

Abstract 2565 ¡ª Harnessing the immune temperature to predict and personalize radiotherapy
Presenter: Awino Maureiq Ojwang, Ph.D.

Abstract 2606 ¡ª Machine learning-based prognostic clinical-genomic model of disease recurrence after chemoradiation and durvalumab in unresectable stage 2-3 NSCLC
Presenter: Kayeong Shin, M.D.

Abstract 2614 ¡ª LLM-driven extraction of NI-RADS and imaging tumor characteristics to enhance oropharyngeal cancer survivorship surveillance
Presenter: Wenye Song, M.D., Ph.D.

Abstract 2616 ¡ª Natural killer cells inhibit radiation induced anti-tumor immune responses
Presenter:

Abstract 2641 ¡ª Single-dose FLASH vs. conventional-dose-rate proton effect on immune modulation in murine prostate cancer models
Presenter:

Abstract 2669 ¡ª Testing adaptive radiation fractionation in head and neck cancer using digital twins of clinical trials
Presenter: Mohammad Zahid, Ph.D.

3¨C4 p.m.

Abstract 2774 ¡ª Local control in metastatic breast cancer: Outcomes of hypofractionated radiotherapy and SBRT for locoregional oligoprogression during systemic therapy
Presenter: Esengul Kocak, M.D.

Abstract 2778 ¡ª Radiation therapy for breast cancer: Impact of DNA repair gene mutations on oncologic outcomes
Presenter: Forrest Kwong, M.D.

Abstract 2797 ¡ª An analysis of acute-on-chronic pain and opioid dependency in a prospective head and neck cancer cohort treated with radiation therapy
Presenter: Md Mahin, Ph.D.

Abstract 2815 ¡ª Response-directed radiotherapy after methotrexate-based systemic therapy for patients with primary CNS lymphoma
Presenter: Ansel Nalin, M.D., Ph.D.

Abstract 2823 ¡ª Long-term skin-related quality of life in patients receiving post-operative radiation therapy for cutaneous melanoma
Presenter: Kelsey Nordlund

Abstract 2835 ¡ª Disease control following radiotherapy for limited-site relapse of follicular lymphoma
Presenter: Pranalee Patel, M.D.

Abstract 2836 ¡ª Shortening adjuvant photon and proton irradiation (SAPPHIRe-II) prospective clinical trial
Presenter: Jane Pearce, M.D.

Abstract 2857 ¡ª Skin-related quality of life during radiotherapy across diverse Fitzpatrick skin types and its association with radiation dermatitis
Presenter: Aya Salem, M.D.

Abstract 2897 ¡ª Prospective evaluation of acute cutaneous toxicity during proton vs. photon radiotherapy for patients with head and neck cancer and varied baseline skin pigmentation
Presenter: Rehema Thomas, M.D.

Abstract 2921 ¡ª Phase 2 study of low dose bridging radiotherapy prior to axicabtagene-ciloleucel in patients with relapsed/refractory follicular lymphoma
Presenter:

4¨C5 p.m.

Abstract 2537?¡ª Targeting radiation-triggered cell-surface GRP78 via antibody-drug conjugate for gastric cancer? 
Presenter:? P.M. Quan Mai

12:30¨C1:45 p.m.

Abstract 2988 ¡ª A data-driven quality assurance for auto-segmentation model updates using a localized anisotropic margin metric
Presenter: Jingwei Duan, Ph.D.

Abstract 3014 ¡ª Machine learning-based prediction of regional liver volume response after radiotherapy in patients with liver malignancies
Presenter: Aashish Gupta

Abstract 3080 ¡ª Considerations of plan adaptation and CBCT-based accumulated dose in the prediction of patient-reported xerostomia post radiotherapy for oropharyngeal cancer patients
Presenter: Androniki Mitrou

Abstract 3148 ¡ª Dosimetric impact of intra-delivery motion in stereotactic body radiotherapy to the prostate and dominant lesion
Presenter: Ka Ho Tam, Ph.D.

Abstract 3171 ¡ª Real-Time tracking for MR-LINAC based spine stereotactic radiosurgery
Presenter: Zhiheng Wang, Ph.D.

Abstract 3172 ¡ª End-to-end test of using three-dimensional rotational angiogram for arteriovenous malformations GammaKnife radiosurgery with a grid phantom
Presenter: Zhiheng Wang, Ph.D.

Abstract 3177 ¡ª Imaging biomarkers for early detection, monitoring and prediction of radiotherapy-related side effects: A scoping review
Presenter: Natalie West

2:15¨C3:30 p.m.

Abstract 3238 ¡ª Safety and clinical outcomes of combining radiotherapy with lutetium-177-PSMA therapy in metastatic castrate-resistant prostate cancer
Presenter: Patrick Carriere, M.D., Ph.D.

Abstract 3262 ¡ª Clinical outcomes of rectal wall infiltration following hydrogel spacer placement: A single-institution retrospective study
Presenter: Zakaria El Kouzi, M.D.

Abstract 3274 ¡ª Skeletal-related events after radiotherapy for non-spine bone metastases in renal cell carcinoma
Presenter: Harshath Gupta, M.D.

Abstract 3374 ¡ª Impact of short-term ADT on survival in unfavorable intermediate-risk prostate cancer treated with proton-beam radiotherapy: A retrospective cohort study
Presenter: Kayeong Shin, M.D.

Abstract 3375 ¡ª Pelvic radiotherapy increases severe lymphopenia in prostate cancer
Presenter: Kayeong Shin, M.D.

Abstract 3731 ¡ª Cervicovaginal bacterial microbiome remodeling after brachytherapy in patients with locally advanced cervical cancer patient treated with chemoradiation with or without therapeutic HPV vaccine
Presenter: Tissana Prasartseree, M.D.

Abstract 3741 ¡ª Molecular subtypes in patients with recurrent endometrial cancer treated with definitive radiation
Presenter: Lauren Bendesky, M.D.

Abstract 3735 ¡ª MCT inhibition targets cervical cancer in lactate enriched microenvironments
Presenter: David Lo

Abstract 3794 ¡ª A dosimetric feasibility of UPFRONT single-fraction brachy-like MR-guided SBRT followed by chemoradiation and brachytherapy as a radical re-sequencing therapy to boost radio-immunopotentiation in cervical cancer
Presenter: Tissana Prasartseree, M.D.

3:45¨C5 p.m.

Abstract 3447 ¡ª Systemic immune activation by mRNA vaccination synergizes with immune checkpoint inhibition and radiotherapy: A single-institution analysis
Presenter: Sage Copling

Abstract 3468 ¡ª Serial MRI-informed proliferation-saturation index modeling for risk-adapted radiotherapy in HPV-positive oropharyngeal cancer
Presenter: Lois Okereke

Abstract 3522 ¡ª A randomized study of head and neck radiotherapy with or without customized 3D printed oral stents
Presenter:

Abstract 3547 ¡ª Pulsed targeted consolidative radiotherapy for patients with polymetastatic NSCLC
Presenter: Jennifer Livschitz, M.D.

Abstract 3564 ¡ª Beyond overlap metrics: Uncertainty-based triage for pathology-anchored QA of nodal autosegmentation in HPV-positive oropharyngeal cancer
Presenter: Yehia Mohamed, M.D.

Abstract 3622 ¡ª Safety and efficacy of proton beam therapy vs. IMRT for postoperative radiotherapy in non-small cell lung cancer: A systematic review and meta-analysis 
Presenter: Kayeong Shin, M.D.